Endothelial‐to‐mesenchymal transition (EndMT) is a poorly understood phenomenon that leads to endothelial cells acquiring a variety of different mesenchymal fates. This results in a number of pathological consequences of considerable clinical significance in diseases ranging from cavernous malformations in the brain to tissue fibrosis, atherosclerosis, and cancer. Importantly, while there appears to be a number of different triggers activating EndMT, the final common pathway driving the transition appears to be the same.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: